Clinical Trial in Patients Diagnosed With Immune Thrombocytopenic Purpura (ITP)

Clinical Trial to Evaluate the Efficacy and the Safety of IGIV3I Grifols 10% (Human Intravenous Immunoglobulin) in Patients Diagnosed With Immune Thrombocytopenic Purpura

The purpose of this study is to determine whether IGIV3I Grifols 10% is effective in the treatment of immune thrombocytopenic purpura.

Study Overview

• Status: Completed
• Conditions: Immune (Idiopathic) Thrombocytopenic Purpura
• Intervention / Treatment: Biological: IGIV3I Grifols

Detailed Description

To determine if IGIV3I Grifols 10% is a consistently effective treatment in patients diagnosed with immune thrombocytopenic purpura with respect to:

1. Increase of platelet count ≥ 50x10^9/L (primary objective).
2. Time taken for the platelet count to reach ≥ 50x10^9/L.
3. The length of time the platelet count remains ≥ 50x10^9/L.
4. The maximum platelet level.
5. Regression of bleeding episodes during the first 10 or 14 days.

To determine if IGIV3I Grifols 10% is safe with respect to:

Nature, severity and frequency of adverse reactions during and after infusions by percentage of subjects and percentage of infusions.

• Study Type: Interventional
• Enrollment (Actual): 18
• Phase: Phase 3

Contacts and Locations

Study Locations

• Russian Federation
  • Moscow, Russian Federation
    • Federal Research Clinical Centre of Pediatric Hematology, Oncology and Immunology Roszdrava
  • Moscow, Russian Federation
    • Haematology Research Centre of Russian Academy of Medical Science
• Spain
  • Barcelona, Spain
    • Hospital General Vall d´Hebron
  • Leon, Spain
    • . Hospital de León
  • Madrid, Spain
    • Hospital General Universitario La Paz
  • Valencia, Spain
    • Hospital Universitario La Fe
• United Kingdom
  • Middlesex, United Kingdom, UB8 3NN
    • Hillingdon Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 82 years (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Be aged between 18 and 82 at the time of written consent.

2. Have confirmed diagnosis of chronic ITP and fulfil all the following criteria:

   • irrelevant history except for the symptoms of bleeding,
   • pattern of bleedings associated with platelet disorders,
   • physical examination irrelevant for the ITP, except for the signs of bleeding,
   • isolated thrombocytopenia in the blood count; apart from thrombocytopenia, the blood count is normal for the patient's age, or if abnormal, readily explained,
   • peripheral blood smear consistent with ITP: thrombocytopenia with platelets of normal size or slightly larger than normal, with absence of platelet clumps and giant platelets; normal red blood cell and white blood cell morphology,
   • confirmed diagnosis of immune thrombocytopenic purpura or, when any abnormal finding is present, additional diagnostic evaluation excludes other causes of thrombocytopenia.
   • Previous known diagnosis of ITP for at least 3 months.
3. To show a platelet count platelet count ≤ 20x10^9/L at the moment of the first infusion with the study product.
4. Have read the patient information and consent sheet, agreed to participate in the trial, and signed the consent sheet.
5. Be expected to receive treatment over 5 days and follow-up for 3 months.
6. For women of childbearing age, use adequate contraceptive method such as oral contraceptives, intrauterine device or tubal ligation during one-month period after the first infusion in the study.

Exclusion Criteria:

1. Have immune thrombocytopenia secondary to other pathologies or drug mediated thrombocytopenia.
2. Have a known diagnosis of other autoimmune diseases, established in the medical history and laboratory findings with positive results for the determination of antinuclear antibodies, anti-cardiolipin antibodies, lupus anticoagulant or direct Coombs test.
3. Present important active bleeding due to other reasons apart from the ITP.
4. Exhibit an identifiable alternative cause of their thrombocytopenia, such as splenomegaly, family thrombocytopenia, bacteraemia, sepsis or active infection requiring or not therapy.
5. Are presenting renal dysfunction.
6. Have non-controlled arterial hypertension.
7. Have documented liver cirrhosis or any hepatic disorder with alanine aminotransferase (ALT) levels 2.5 times or more than the normal upper limit or bilirubin greater than 2 mg/dL.
8. Are presenting a cardiac disease including a history of coronary artery disease, angina pectoris or congestive heart failure.
9. Present known infection due to HIV or hepatitis C virus (HCV).
10. Have been previously treated with IVIG or anti-D immunoglobulin being unresponsive.
11. Have a history of serious adverse reactions or non-serious but frequent adverse reactions to intravenous immune globulin (IVIG) preparations or other products derived from blood.
12. Have known allergies to any IGIV3I Grifols components, such as D-sorbitol.
13. Are simultaneously participating in other clinical studies or have received an investigational drug in the 3 months prior to the start of the study.
14. Have been involved in the present study and being treated with the formulation at 5% (IGIV3I Grifols 5%).
15. Have conditions that might affect patient compliance.
16. Are unable to provide a storage serum sample just before the first dose of IGIV3I Grifols.
17. Are pregnant or nursing an infant child or unwilling to practice adequate birth control in 1-month period after the first infusion in the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: NA
• Interventional Model: SINGLE_GROUP
• Masking: NONE

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: 1 treatment group with IGIV3I Grifols; Open label, non-randomized treatment group with IGIV3I Grifols Each patient received a total dose of 2 g/kg IGIV3I Grifols, given intravenously over either 2 days or 5 days in divided doses.	Biological: IGIV3I Grifols; Immune Globulin Intravenous (Human); Other Names: IGIV

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Responder Patients	The primary efficacy endpoint was the proportion of patients who reached a platelet count ≥ 50x10^9/L.	At any time during the study period (The platelet count was measured at Days 1-6, 10, 14. 21, 30, 60, 90).

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Maximum Platelet Level Reached During the Follow-up Period	Platelet count was measured at various time points in the follow-up period after infusion.	During the follow-up period (time points: Days 6, 10, 14, 21, 30, 60, 90 post-first infusion day [Day 1])
Time to Reach Platelet Count ≥ 50x10^9/L (≤ Days)	The time taken for the platelet count to reach ≥ 50x10^9/L from first dose	At any time during the study period (time points: Days 1-6, 10, 14, 21, 30, 60, 90 post-first infusion day [Day 1])
Length of Time Platelet Count Remains ≥ 50x10^9/L (≥ Days)	Length of time platelet count remained ≥ 50x10^9/L from first dose (Day 1)	At any time during the study period (up to 3 months [90 days])
Regression of Hemorrhages.	Percentage of subjects with regression of hemorrhages of Types 1 to 3: Type 0: Patients without symptoms of bleeding at the first infusion continue without presenting spontaneous bleeding; Type 1: Patients with bleeding symptoms at the first infusion had a reduction of the size of large ecchymoses, and no spontaneous appearance of new ecchymoses; Type 2: Patients with bleeding symptoms at the first infusion had a decrease in the number of cutaneous petechiae, or the extent of the affected area of the body decreased; Type 3: Patients had active mucosal bleedings at the first infusion, these episodes stopped without re-bleeding, and there was no occurrence of new spontaneous mucosal hemorrhages (e.g., gingival bleeding, epistaxis)	First 10 to14 days since the first infusion day (Day 1)
Frequency of Adverse Reactions During and After Infusions by Percentage of Patients	All adverse events (AEs) are tabulated and summarized. The incidence, severity, and causal relationship of the AEs to IGIV3I Grifols are presented by system organ class after medical coding according to the version 15.0 of Medical Dictionary for Regulatory Activities (MedDRA). The frequency of patients with at least one AE and adverse drug reactions are estimated.	At any time during the study period (from patient's signature of the informed consent form until 3 months of follow-up)
Frequency of Adverse Reactions During and After Infusions by Percentage of Infusions	All adverse events (AEs) are tabulated and summarized. The incidence, severity, and causal relationship of the AEs to IGIV3I Grifols are presented by system organ class after medical coding according to the version 15.0 of Medical Dictionary for Regulatory Activities (MedDRA). The frequency of infusions associated with at least one AE and adverse drug reactions are estimated.	At any time during the study period (from patient's signature of the informed consent form until 3 months of follow-up)
Changes in Vital Signs and Clinically Relevant Changes in Laboratory Parameters After the Infusions, Including Renal Function (Creatinine Levels)	Laboratory parameters at each treatment day and visit are summarized by patient. Results were marked as normal/abnormal (whether the result is below, within or above the respective reference range) and relevant/irrelevant (as determined by the investigator). The number of abnormal values considered clinically relevant changes (based on the investigator's judgment) was listed.	At any time during the study period (from patient's signature of the informed consent form until 3 months of follow-up)
Viral Safety Through the Investigation of Patients Virology Status (Hepatitis A Virus [HA	The results of HIV-1 and -2 antibodies, HCV antibody, HBsAg, HBV antibodies, HAV antibodies, HIV nucleic acid amplification test [NAT], and HCV NAT on Day 1, Day 14, and at Month 1, Month 2 and Month 3 were recorded for several of these markers (as appropriate). A comparison of negative viral markers on Day 1 and Month 3 was performed	At any time during the study period (from patient's signature of the informed consent form until 3 months of follow-up)

Collaborators and Investigators

• Sponsor: Instituto Grifols, S.A.
• Investigators: Principal Investigator: María Teresa Álvarez, MD, Hospital General Universitario La Paz

Study record dates

Study Major Dates

• Study Start: February 1, 2008
• Primary Completion (ACTUAL): December 1, 2013
• Study Completion (ACTUAL): December 1, 2013

Study Registration Dates

• First Submitted: June 16, 2008
• First Submitted That Met QC Criteria: June 16, 2008
• First Posted (ESTIMATE): June 17, 2008

Study Record Updates

• Last Update Posted (ESTIMATE): February 8, 2016
• Last Update Submitted That Met QC Criteria: January 9, 2016
• Last Verified: January 1, 2016

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Immune System Diseases; Autoimmune Diseases; Hematologic Diseases; Hemorrhage; Hemorrhagic Disorders; Blood Coagulation Disorders; Skin Manifestations; Thrombocytopenia; Blood Platelet Disorders; Thrombotic Microangiopathies; Purpura; Purpura, Thrombocytopenic; Purpura, Thrombocytopenic, Idiopathic
• Other Study ID Numbers: IG202